Prime Medicine, Inc. (PRME)
3.67
-0.06
(-1.61%)
USD |
NASDAQ |
Oct 23, 16:00
3.60
-0.07
(-1.91%)
After-Hours: 20:00
Prime Medicine Enterprise Value : 680.71M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 680.71M |
| October 22, 2026 | 691.56M |
| October 21, 2026 | 706.02M |
| October 20, 2026 | 725.90M |
| October 19, 2026 | 709.63M |
| October 16, 2026 | 644.57M |
| October 15, 2026 | 669.87M |
| October 14, 2026 | 583.12M |
| October 13, 2026 | 617.46M |
| October 12, 2026 | 669.87M |
| October 09, 2026 | 738.55M |
| October 08, 2026 | 664.45M |
| October 07, 2026 | 722.28M |
| October 06, 2026 | 649.99M |
| October 05, 2026 | 597.57M |
| October 02, 2026 | 556.00M |
| October 01, 2026 | 557.81M |
| September 30, 2026 | 569.56M |
| September 29, 2026 | 575.89M |
| September 28, 2026 | 537.03M |
| September 25, 2026 | 541.55M |
| September 24, 2026 | 572.27M |
| September 23, 2026 | 583.12M |
| September 22, 2026 | 657.22M |
| September 21, 2026 | 593.96M |
| Date | Value |
|---|---|
| September 18, 2026 | 581.31M |
| September 17, 2026 | 584.92M |
| September 16, 2026 | 559.62M |
| September 15, 2026 | 584.92M |
| September 14, 2026 | 592.15M |
| September 11, 2026 | 583.12M |
| September 10, 2026 | 622.88M |
| September 09, 2026 | 644.57M |
| September 08, 2026 | 660.83M |
| September 04, 2026 | 686.14M |
| September 03, 2026 | 687.94M |
| September 02, 2026 | 680.71M |
| September 01, 2026 | 662.64M |
| August 31, 2026 | 666.25M |
| August 28, 2026 | 669.87M |
| August 27, 2026 | 675.29M |
| August 26, 2026 | 664.45M |
| August 25, 2026 | 687.94M |
| August 24, 2026 | 604.80M |
| August 21, 2026 | 630.11M |
| August 20, 2026 | 603.00M |
| August 19, 2026 | 657.22M |
| August 18, 2026 | 568.66M |
| August 17, 2026 | 590.34M |
| August 14, 2026 | 575.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.205B |
| Beam Therapeutics, Inc. | 1.578B |
| Twist Bioscience Corp. | 8.696B |
| Moderna, Inc. | 75.99B |
| Q32 Bio, Inc. | 104.35M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.11M |
| Revenue (Quarterly) | 1.154M |
| Total Expenses (Quarterly) | 43.26M |
| EPS Diluted (Quarterly) | -0.2376 |
| Gross Profit Margin (Quarterly) | -54.68% |
| Profit Margin (Quarterly) | -3.65K% |
| Earnings Yield | -29.58% |
| Normalized Earnings Yield | -29.80 |